TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06587828

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.

Intervention type: PROCEDURE
Intervention: Companion blood samples with procedure
Description: Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.
Study: NCT06591754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISTDP
Description: Both the individual therapy and the group therapy is based on ISTDP (Intensive Short-Term Dynamic Psychotherapy), an affect-focused psychodynamic therapy method. The therapy focus on the relationship between feelings, anxiety and dysfunctional emotion regulation (i.e. defenses). The purpose is to increase the capacity of anxiety regulation in the patient and to help the patient identify the dysfunctional patterns developed to avoid internal stress and then gradually approach previously warded of feelings. The individual therapy consists of 25 weekly sessions. The group treatment consists of 18 weekly sessions and is structured in three phases. Phase one: Psychoeducation about anxiety and exercises in anxiety regulation. Phase two: patients takes turn to observe their own anxiety and defenses together with a therapist. Phase three: Every session two patients will work with a chosen problem and identify defenses, anxiety and feelings together with a therapist in front of the group.
Study: NCT06603480

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Aerobic exercise (moderate intensity) at 50-70% of maximum heart rate for 60 minutes, 3 days a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients who started Metformin 2\*1
Study: NCT06601062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-BE
Description: Clinicians and their patients use the newly developed telehealth tool to support their use of CBT during session
Study: NCT06599892

Intervention type: OTHER
Intervention: Intervention mapping
Description: Intervention mapping is a model combining patient and professional questionnaires and a qualitative survey using individual interviews with patients and focus groups with professionals to identify the obstacles and levers to change at the level of patients, professionals and organisations.

Intervention type: OTHER
Intervention: Intervention mapping
Description: Intervention mapping is a model combining patient and professional questionnaires and a qualitative survey using individual interviews with patients and focus groups with professionals to identify the obstacles and levers to change at the level of patients, professionals and organisations.
Study: NCT06591325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The RT program was performed in the morning and in groups, three days per week (Mondays, Wednesdays, and Fridays), in the University fitness facility over 12 weeks. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise session) with substantial RT experience to ensure consistent and safe exercise performance. Throughout the intervention period, the RT program was carried out on machines and free weights (Ipiranga Fitness, Presidente Prudente, SP, Brazil). The training program was carried out in groups. Participants performed four exercises for the trunk and upper limbs (chest press, seated row, triceps pushdown, preacher curl) and four exercises for the lower limbs (horizontal leg press, leg extension, lying leg curl, seated calf raise) in three sets of 10-15 repetitions based on previous guidelines (9,22).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: maintaining the daily routine
Study: NCT06595563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered IV at a dose of 3.6 mg/kg every 3 weeks. (21 days +/- 3 days) until disease progression, unacceptable toxicity or request of the subject to withdraw from the study. The total dose will depend on the subject's weight on day 1 of each T-DM1 cycle.
Study: NCT06594679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tosylate Monohydrate
Description: Combination of niraparib and abemaciclib
Study: NCT06600399

Intervention type: DIAGNOSTIC_TEST
Intervention: glioblastoma
Description: All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval
Study: NCT06599788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-paced work
Description: Participants will choose their own pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-paced work
Description: Participants will choose their own pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-paced work
Description: Participants will choose their own pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-paced work
Description: Participants will choose their own pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-pace work
Description: Participants will work at a 25% reduced pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-pace work
Description: Participants will work at a 25% reduced pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-pace work
Description: Participants will work at a 25% reduced pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced-pace work
Description: Participants will work at a 25% reduced pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased-pace work
Description: Participants will work at a 25% increased pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased-pace work
Description: Participants will work at a 25% increased pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased-pace work
Description: Participants will work at a 25% increased pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increased-pace work
Description: Participants will work at a 25% increased pace during the box-lifting protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional rest breaks
Description: Participants will choose their own pace during the box-lifting protocol and have superimposed 5 minutes of rest every 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional rest breaks
Description: Participants will choose their own pace during the box-lifting protocol and have superimposed 5 minutes of rest every 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional rest breaks
Description: Participants will choose their own pace during the box-lifting protocol and have superimposed 5 minutes of rest every 15 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional rest breaks
Description: Participants will choose their own pace during the box-lifting protocol and have superimposed 5 minutes of rest every 15 minutes.
Study: NCT06590285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based Educational Intervention
Description: The program's educational content is designed to engage patients in the science of sleep and recovery. Segments like The Sleep Adventure demystify complex neurobiological processes in an accessible format, aligning with emerging trends in patient education that focus on engagement and knowledge empowerment. Concurrently, the program's physical activity component is meticulously crafted, offering safe, supportive exercises that correspond with the treatment stages of alloHSCT patients. This aspect draws upon evidence highlighting the importance of sustained physical activity during intensive treatments to enhance overall recovery and quality of life. Additionally, the program comprehensively addresses sleep disturbances, prevalent in HSCT patients, through in-depth exploration and evidence-based, non-pharmacologic management strategies, reflecting the significant impact of sleep quality on patient recovery and long-term health outcomes.
Study: NCT06595745

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Wolbachia induced incompatible mating
Description: The intervention will be performed by weekly release of male Aedes aegypti carrying Wolbachia (wAlbB strain) to mate with wild females, resulting in the death of their eggs for birth control. Before release, these males will be irradiated with X-rays to minimize the chance of any residual fertile female releases. The intervention will lead to Ae. aegypti population suppression or even elimination and preventing dengue transmission in release sites.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard traditional chemical mosquito control
Description: Traditional and commonly used chemical insecticide will be applied to reduce the mosquito population

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard traditional chemical mosquito control
Description: Traditional and commonly used chemical insecticide will be applied to reduce the mosquito population
Study: NCT06595797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: HRS9531
Study: NCT05365217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonacog beta pegol
Description: Nonacog beta pegol is administered as intravenous injections. Participants will receive nonacog beta pegol as prophylaxis, as on-demand for treatment of bleeding episodes and in relation to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonacog beta pegol
Description: Nonacog beta pegol is administered as intravenous injections. Participants will receive nonacog beta pegol as prophylaxis, as on-demand for treatment of bleeding episodes and in relation to surgery.
Study: NCT06595797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: HRS9531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: HRS9531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531placebo
Description: HRS9531placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531placebo
Description: HRS9531placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531placebo
Description: HRS9531placebo
Study: NCT06592807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative Warm Socks
Description: The socks to be used in the study were provided by the researcher. The socks were suitable for foot sizes 36-45. The socks were white and made of cotton fabric. The socks were sterilized in an autoclave before use. The socks were put on the patients just before the surgery. The socks were heated to 40 degrees with an intravenous fluid warming machine.The socks remained on the patients feet throughout the surgery. After the surgery, the patients socks were removed and new heated socks were put on. The socks were kept on the patients feet for 1 hour. All socks were used for single use.
Study: NCT04716231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Once weekly subcutaneous (SC) injections by prefilled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Atacicept
Description: Once weekly subcutaneous (SC) injections by prefilled syringe
Study: NCT04983680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT
Description: Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training. In this study, MBCT has been adapted to include education about cardiac health and fear of recurrence, and the intervention is delivered remotely via synchronous group videoconference. There is 15-20 minutes of daily mindfulness practice between sessions. Participants are provided a home practice record form and asked to submit the completed form to study staff each week.
Study: NCT05304195

Intervention type: DIAGNOSTIC_TEST
Intervention: Glucocerebrosidase
Description: Blood sample (10ml) for GCase activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Glucocerebrosidase
Description: Blood sample (10ml) for GCase activity

Intervention type: GENETIC
Intervention: GBA gene
Description: Blood sample (10ml) for variants or mutations of the GBA gene

Intervention type: GENETIC
Intervention: GBA gene
Description: Blood sample (10ml) for variants or mutations of the GBA gene

Intervention type: DIAGNOSTIC_TEST
Intervention: Macrophage biomarkers
Description: Blood sample (20ml) for macrophage biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: Macrophage biomarkers
Description: Blood sample (20ml) for macrophage biomarkers
Study: NCT06600308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk tests
Description: Performance of the following walking tests using inertial measurement units: TUG; 10 m test at a comfortable and fast speed and TM6 (according to the recommendations of the American Thoracic Society).~At the end of each walking test, measurement of the difficulty of exertion using the Borg scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ecological (real-life) assessment of walking ability
Description: Delivery of an actimeter, inertial units and logbook for ecological assessment (in real life) of walking ability for 7 days
Study: NCT06601790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate application of the Smart Homespital system
Description: The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed application of the Smart Homespital system after 3 months
Description: The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
Study: NCT06586203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polygenic Risk Score
Description: The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.
Study: NCT06586242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
Description: 200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
Description: 200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w
Study: NCT06592300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Film coated Tablet
Description: The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide Film coated Tablet
Description: The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy® film-coated tablets
Description: The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemlidy® film-coated tablets
Description: The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
Study: NCT06599515

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic surgical platform
Description: robot-assisted laparoscopic inguinal hernia repair (rTAR)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic surgical platform
Description: robot-assisted laparoscopic inguinal hernia repair (rTAR)
Study: NCT04852172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D5 1/2NS
Description: Saline
Study: NCT06592625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab
Study: NCT06603857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CE Ferulic
Description: CE Ferulic serum regimen combined with laser treatment

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Vehicle serum regimen combined with laser treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1927nm (Clear and Brilliant Perméa®)
Description: non-ablative fractional diode laser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1927nm (Clear and Brilliant Perméa®)
Description: non-ablative fractional diode laser
Study: NCT05134428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADAM System
Description: The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADAM System
Description: The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADAM System
Description: The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADAM System
Description: The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
Study: NCT06593860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote speech rehabilitation
Description: Two types of intervention will be provided via online to 32 dyads of people with Parkinson's disease: (1) speech therapy (PD patients) and (2) family education/training (PD families). Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks.